Copeptin
8
2
2
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
13%
1 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (8)
Serum Copeptin as Biomarker for Diagnosis and Classification of Polyuric Primary Monosymptomatic Nocturnal Enuresis
The Trend of Copeptin Levels and Its Clinical Value for Postoperative CDI in Pediatric Patients After NSI in ICU
Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome
Rapid Identification of MINOCA Based on Novel Biomarkers
Copeptin Serum Level in Liver Transplant Recipients
The Effect of Midazolam Premedication on Copeptine Concentration in Blood
Copeptin Changes After Food Intake
Biomarkers In Seizure To Predict Recurrence and Severe Outcomes